Numinus Wellness Inc. Stock

Equities

NUMI

CA67054W1032

Biotechnology & Medical Research

Market Closed - Toronto S.E. 15:58:33 2024-06-25 EDT 5-day change 1st Jan Change
0.045 CAD -10.00% Intraday chart for Numinus Wellness Inc. -10.00% -59.09%
Sales 2024 * 21.91M 16.04M Sales 2025 * 33.35M 24.42M Capitalization 14.42M 10.56M
Net income 2024 * -16M -11.72M Net income 2025 * -3M -2.2M EV / Sales 2024 * 0.66 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.43 x
P/E ratio 2024 *
-0.75 x
P/E ratio 2025 *
-4.5 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.07%
More Fundamentals * Assessed data
Dynamic Chart
Numinus Wellness Signs Letter of Intent to Buy MedBright AI Investments MT
Numinus Wellness Brief: MedBright AI Announcing Strategic Acquisition by Numinus Wellness MT
Numinus Wellness Inc. Appoints Jaime Gerber to Numinus Intelligence Board CI
Numinus Wellness Inc. executed a letter of intent to acquire MedBright AI Investments Inc. from Michael Dalsin and others for CAD 9.6 million. CI
Numinus Wellness Inc. Announces Its Cedar Clinical Research Select for Cybin's Phase 3 Pivotal Multinational Clinical Trial of CYB003 CI
Numinus Wellness Comments on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD CI
Transcript : Numinus Wellness Inc. - Shareholder/Analyst Call
Numinus Wellness Secures Health Canada Approval for Study Into Group Model For MDMA-Assisted Therapy MT
Numinus Wellness Brief: Says Received Health Canada Approval for Study into Group Model for MDMA-Assisted Therapy MT
Numinus Wellness Receives Health Canada Approval for Study into Group Model for MDMA-Assisted Therapy CI
Numinus Wellness to Focus on U.S. Operations as it Transitions Out of Canada MT
Numinus Wellness Brief: Announces a strategic plan designed to streamline expenses and "Sharpen" focus on Higher-growth U.S. operations MT
Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003 MT
Cybin Selects Numinus Wellness Inc.'s Cedar Clinical Research as clinical research site for Its Phase 3 Study of CYB003 CI
Transcript : Numinus Wellness Inc., Q2 2024 Earnings Call, Apr 15, 2024
More news

Latest transcript on Numinus Wellness Inc.

1 day-10.00%
1 week-10.00%
Current month-30.77%
1 month-35.71%
3 months-52.63%
6 months-62.50%
Current year-59.09%
More quotes
1 week
0.05
Extreme 0.045
0.06
1 month
0.04
Extreme 0.04
0.08
Current year
0.04
Extreme 0.04
0.20
1 year
0.04
Extreme 0.04
0.27
3 years
0.04
Extreme 0.04
1.18
5 years
0.04
Extreme 0.04
2.45
10 years
0.04
Extreme 0.04
2.45
More quotes
Managers TitleAgeSince
Chief Executive Officer - 62-06-25
President - 18-12-31
Chief Tech/Sci/R&D Officer - 22-06-09
Members of the board TitleAgeSince
Director/Board Member 67 19-01-27
Director/Board Member 75 12-03-08
Chief Executive Officer - 62-06-25
More insiders
Date Price Change Volume
24-06-25 0.045 -10.00% 156,080
24-06-24 0.05 0.00% 309,883
24-06-21 0.05 -9.09% 1,131,993
24-06-20 0.055 +10.00% 1,687,963
24-06-19 0.05 0.00% 379,279

Delayed Quote Toronto S.E., June 25, 2024 at 03:58 pm

More quotes
Numinus Wellness Inc. is a Canada-based mental health care company. The Company helps people to heal and be well through the development and delivery of mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Company's segments include Clinical Research Operations, Canadian Clinic Network and US Clinic Network. Its Clinical Research Operations is focused on licensed psychedelic research and provides clinical research management services to academic institutions and biotechnology companies. Its Canadian Clinic Network segment includes wellness clinics based in Canada offering clinical services, including traditional therapy and counseling, ketamine-assisted therapies, mindfulness programs, and virtual psychotherapy. The US Clinic Network segment includes wellness clinics based in the United States that offers clinical services, such as psychedelic-assisted therapies, transcranial magnetic stimulation, and psychiatric and medical model management.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.045
Average target price
-
Consensus